UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Clinical pharmacokinetics, 2010-08, Vol.49 (8), p.493-507

2010

Volltextzugriff (PDF)

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

Computer methods and programs in biomedicine, 2011, Vol.101 (1), p.72-79

2011

Volltextzugriff (PDF)

Concise Review: Clinical Relevance of Drug–Drug and Herb–Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P‐glycoprotein)

The oncologist (Dayton, Ohio), 2007-08, Vol.12 (8), p.927-941

2007

Volltextzugriff (PDF)

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

Investigational new drugs, 2009-02, Vol.27 (1), p.31-40

2009

Volltextzugriff (PDF)

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

British journal of cancer, 2021-02, Vol.124 (4), p.728-735

2021

Volltextzugriff (PDF)

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

European journal of cancer (1990), 2017-05, Vol.76, p.144-151

2017

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

Clinical pharmacokinetics, 2017-09, Vol.56 (9), p.987-997

2017

Volltextzugriff (PDF)

Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

Cancer chemotherapy and pharmacology, 2007-09, Vol.60 (4), p.523-533

2007

Volltextzugriff (PDF)

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years

Cancer chemotherapy and pharmacology, 2013-03, Vol.71 (3), p.749-763

2013

Volltextzugriff (PDF)

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA

Investigational new drugs, 2013-10, Vol.31 (5), p.1125-1135

2013

Volltextzugriff (PDF)

Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183

Investigational new drugs, 2014-12, Vol.32 (6), p.1083-1095

2014

Volltextzugriff (PDF)

Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb–drug interactions in cancer patients

Cancer treatment reviews, 2013-11, Vol.39 (7), p.773-783

2013

Volltextzugriff (PDF)

Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction

Cancer chemotherapy and pharmacology, 2015-12, Vol.76 (6), p.1285-1295

2015

Volltextzugriff (PDF)

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Cancer chemotherapy and pharmacology, 2009-06, Vol.64 (1), p.115-122

2009

Volltextzugriff (PDF)

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients

Clinical pharmacokinetics, 2017-03, Vol.56 (3), p.293-303

2017

Volltextzugriff (PDF)

The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers

European journal of clinical pharmacology, 2013-11, Vol.69 (11), p.1883-1890

2013

Volltextzugriff (PDF)

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

Cancer chemotherapy and pharmacology, 2020-05, Vol.85 (5), p.917-930

2020

Volltextzugriff (PDF)

Phase I pharmacological study of continuous chronomodulated capecitabine treatment

Pharmaceutical research, 2020-05, Vol.37 (5), p.89, Article 89

2020

Volltextzugriff (PDF)

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose

Investigational new drugs, 2018-12, Vol.36 (6), p.1006-1015

2018

Volltextzugriff (PDF)

A sensitive LC–MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2011-01, Vol.879 (1), p.41-48

2011

Volltextzugriff (PDF)

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies

Investigational new drugs, 2016-04, Vol.34 (2), p.184-192

2016

Volltextzugriff (PDF)

A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development

Journal of clinical pharmacology, 2020-03, Vol.60 (3), p.340-350

2020

Volltextzugriff (PDF)

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

Investigational new drugs, 2020-04, Vol.38 (2), p.457-467

2020

Volltextzugriff (PDF)

Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination

Analytical and bioanalytical chemistry, 2013-03, Vol.405 (7), p.2391-2395

2013

Volltextzugriff (PDF)

Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error

Investigational new drugs, 2014-10, Vol.32 (5), p.913-927

2014

Volltextzugriff (PDF)

1 – 25 von 127

Suche als RSS-Feed

Aktive Filter

ThemaPharmacokinetics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(127)
Mit Volltextzugriff
(123)

Publikationsform

Artikel
(127)

Sprache

Englisch
(127)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(118)
Science & Technology
(118)
Humans
(100)
Pharmacology & Pharmacy
(83)
Oncology
(75)
Female
(57)
Adult
(51)
Middle Aged
(51)
Male
(50)
Aged
(44)
Neoplasms - Drug Therapy
(37)
Antineoplastic Agents - Pharmacokinetics
(36)
Pharmacology/toxicology
(36)
Tumors
(36)
Medicine
(33)
Medicine & Public Health
(33)
Biological And Medical Sciences
(31)
Medical Sciences
(31)
Drug Dosages
(30)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

Concise Review: Clinical Relevance of Drug–Drug and Herb–Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P‐glycoprotein)

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA

Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183

Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb–drug interactions in cancer patients

Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients

The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer

Phase I pharmacological study of continuous chronomodulated capecitabine treatment

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose

A sensitive LC–MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies

A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination

Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error

Aktive Filter

Suchergebnisse filtern